Ventripoint Diagnostics Ltd. (VPTDF) 0.0514 $VPTDF
Montefiore Hospital in New York City to Conduct Cardiac Re-Admission Study Using the Ventripoint VMS(TM) Heart Analysis System
Marketwire - Tue Apr 15, 7:49AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that the Montefiore-Einstein Center for Heart and Vascular Care in the Bronx, New York City has received approval to conduct a re-admission study in patients with heart failure to determine if the quantitative assessment of right-heart function using the Ventripoint VMS(TM) Heart Analysis System would enable cardiologists to identify those patients most likely to return and be re-admitted within 30 days. Dr. Mario Garcia and Dr. Ileana Pina are leading the study.
Ventripoint Corporate Update and Resignation of Director
Marketwire - Tue Apr 08, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that following the clearance by the US Food and Drug Administration (FDA) of the VMS(TM) heart analysis system for right ventricle assessment in adult patients with Pulmonary Arterial Hypertension (PAH), the Company has focused on initial marketing strategies which include:
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH).
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency" a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Planned Response to FDA Notification and Expanded Sales Efforts Outside of the United States
ACCESSWIRE - Mon Nov 25, 3:11PM CST
** FDA has Invited the Company to Meet the Review Team **
Ventripoint Receives Response from FDA for Application of VMS (tm) for use in Pulmonary Arterial Hypertension
ACCESSWIRE - Fri Nov 15, 8:02AM CST
Seattle, Washington, November 15, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint" (TSXV:VPT) announces that the FDA has closed its review of the Company's 510(K) application for approval of the Ventripoint Medical System (VMS(TM)) for use in Pulmonary Arterial Hypertension (PAH). The FDA has found that despite achieving an average agreement between VMS and MRI results within the allowable 10% mean difference, the substantial equivalency was not sufficiently proven to warrant approval. The FDA stated that Ventripoint is welcome to submit a new 510(K) application with data that would show substantial equivalency.
IIROC: Halt; VentriPoint Diagnostics Ltd.
Marketwire Canada - Fri Nov 15, 7:17AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
VentriPoint Diagnostics, Legend Gold and Black Iron Featured on Episode 18 of the Next Biggest Winner TV Show This Weekend
Marketwire - Thu Nov 14, 10:54AM CST
The Next Biggest Winner, a leading and nationally televised investment show focusing on small-cap and mid-cap companies, is pleased to announce Episode 18 will be airing across Canada this weekend.
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements.
Montefiore Hospital in New York City to Conduct Cardiac Re-Admission Study Using the Ventripoint VMS(TM) Heart Analysis System
Marketwire - Tue Apr 15, 7:49AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that the Montefiore-Einstein Center for Heart and Vascular Care in the Bronx, New York City has received approval to conduct a re-admission study in patients with heart failure to determine if the quantitative assessment of right-heart function using the Ventripoint VMS(TM) Heart Analysis System would enable cardiologists to identify those patients most likely to return and be re-admitted within 30 days. Dr. Mario Garcia and Dr. Ileana Pina are leading the study. Ventripoint Corporate Update and Resignation of Director
Marketwire - Tue Apr 08, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that following the clearance by the US Food and Drug Administration (FDA) of the VMS(TM) heart analysis system for right ventricle assessment in adult patients with Pulmonary Arterial Hypertension (PAH), the Company has focused on initial marketing strategies which include: IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH). IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency"
a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH). Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Planned Response to FDA Notification and Expanded Sales Efforts Outside of the United States
ACCESSWIRE - Mon Nov 25, 3:11PM CST
** FDA has Invited the Company to Meet the Review Team **
Ventripoint Receives Response from FDA for Application of VMS (tm) for use in Pulmonary Arterial Hypertension
ACCESSWIRE - Fri Nov 15, 8:02AM CST
Seattle, Washington, November 15, 2013 - Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSXV:VPT) announces that the FDA has closed its review of the Company's 510(K) application for approval of the Ventripoint Medical System (VMS(TM)) for use in Pulmonary Arterial Hypertension (PAH). The FDA has found that despite achieving an average agreement between VMS and MRI results within the allowable 10% mean difference, the substantial equivalency was not sufficiently proven to warrant approval. The FDA stated that Ventripoint is welcome to submit a new 510(K) application with data that would show substantial equivalency. IIROC: Halt; VentriPoint Diagnostics Ltd.
Marketwire Canada - Fri Nov 15, 7:17AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
VentriPoint Diagnostics, Legend Gold and Black Iron Featured on Episode 18 of the Next Biggest Winner TV Show This Weekend
Marketwire - Thu Nov 14, 10:54AM CST
The Next Biggest Winner, a leading and nationally televised investment show focusing on small-cap and mid-cap companies, is pleased to announce Episode 18 will be airing across Canada this weekend.
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements. 
